SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Yonekawa Y, Kim IK. Epidemiology and management of uveal melanoma. Hematol Oncol Clin North Am. 2012;26:11691184.
  • 2
    Diener-West M, Reynolds SM, Agugliaro DJ, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol. 2005;123:16391643.
  • 3
    Slingluff CL, Flaherty K, Rosenberg SA, et al. Cutaneous melanoma. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia, PA: Lippincott, Williams & Wilkins; 2008.
  • 4
    Leiter U, Meier F, Schittek B, Garbe C. The natural course of cutaneous melanoma. J Surg Oncol. 2004;86:172178.
  • 5
    Marshall E, Romaniuk C, Ghaneh P, et al. MRI in the detection of hepatic metastases from high-risk uveal melanoma: a prospective study in 188 patients. Br J Ophthalmol. 2013;97:159163.
  • 6
    Frenkel S, Nir I, Hendler K, et al. Long-term survival of uveal melanoma patients after surgery for liver metastases. Br J Ophthalmol. 2009;93:10421046.
  • 7
    Mariani P, Piperno-Neumann S, Servois V, et al. Surgical management of liver metastases from uveal melanoma: 16 years' experience at the Institut Curie. Eur J Surg Oncol. 2009;35:11921197.
  • 8
    Piperno-Neumann S, Chaaba H, Plancher C, et al. Retrospective analysis of 470 metastatic uveal melanoma (MUM) patients managed at Institut Curie between 2000 and 2008. Ann Oncol. 2010;21(suppl 8):viii401. Abstract 3777.
  • 9
    Rivoire M, Kodjikian L, Baldo S, Kaemmerlen P, Négrier S, Grange JD. Treatment of liver metastases from uveal melanoma. Ann Surg Oncol. 2005;12:422428.
  • 10
    Rose DM, Essner R, Hughes TM, et al. Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience. Arch Surg. 2001;136:950955.
  • 11
    Adam R, Chiche L, Aloia T, et al. Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. Ann Surg. 2006;244:524535.
  • 12
    de Ridder J, van Walsum M, Verhoef C, Nagtegaal I, de Wilt J; Dutch Liver Working Group. Hepatic resection for metastatic melanoma in The Netherlands: survival and prognostic factors. Melanoma Res. 2013;23:2732.
  • 13
    Groeschl RT, Nachmany I, Steel JL, et al. Hepatectomy for noncolorectal non-neuroendocrine metastatic cancer: a multi-institutional analysis. J Am Coll Surg. 2012;214:769777.
  • 14
    Pawlik TM, Zorzi D, Abdalla EK, et al. Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease. Ann Surg Oncol. 2006;13:712720.
  • 15
    Pilati PL, Mammano E, Tessari E, et al. Multimodal treatments for liver metastases from melanoma: experience of a single institution. Ann Surg Oncol. 2010;17:(suppl 1):S83. Abstract P155.
  • 16
    Ripley RT, Davis JL, Klapper JA, et al. Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy. Ann Surg Oncol. 2010;17:163170.
  • 17
    Ryu SW, Saw R, Scolyer RA, Crawford M, Thompson JF, Sandroussi C. Liver resection for metastatic melanoma: Equivalent survival for cutaneous and ocular primaries. J Surg Oncol. 2013;108:129135.
  • 18
    Aubin JM, Rekman J, Vandenbroucke-Menu F, et al. Systematic review and meta-analysis of liver resection for metastatic melanoma. Br J Surg. 2013;100:11381147.
  • 19
    Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367:16941703.
  • 20
    Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:25072516.
  • 21
    Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367:107114.
  • 22
    Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358365.
  • 23
    Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711723.
  • 24
    Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:25172526.
  • 25
    Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011;305:23272334.
  • 26
    Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (Anti-PD-1) in melanoma. N Engl J Med. 2013;369:134144.
  • 27
    Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122133.
  • 28
    Bedikian AY, Papadopoulos N, Plager C, Eton O, Ring S. Phase II evaluation of temozolomide in metastatic choroidal melanoma. Melanoma Res. 2003;13:303306.
  • 29
    Homsi J, Bedikian AY, Papadopoulos NE, et al. Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma. Melanoma Res. 2010;20:507510.
  • 30
    Kivelä T, Suciu S, Hansson J, et al. Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma. Eur J Cancer. 2003;39:11151120.
  • 31
    O'Neill PA, Butt M, Eswar CV, Gillis P, Marshall E. A prospective single arm phase II study of dacarbazine and treosulfan as first-line therapy in metastatic uveal melanoma. Melanoma Res. 2006;16:245248.
  • 32
    Pföhler C, Cree IA, Ugurel S, et al. Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study. Anticancer Drugs. 2003;14:337340.
  • 33
    Pons F, Plana M, Caminal JM, et al. Metastatic uveal melanoma: is there a role for conventional chemotherapy? A single center study based on 58 patients. Melanoma Res. 2011;21:217222.
  • 34
    Pyrhönen S, Hahka-Kemppinen M, Muhonen T, et al. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma. Cancer. 2002;95:23662372.
  • 35
    Schmittel A, Scheulen ME, Bechrakis NE, et al. Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma. Melanoma Res. 2005;15:205207.
  • 36
    Schmittel A, Schuster R, Bechrakis NE, et al. A two-cohort phase II clinical trial of gemcitabine plus treosulfan in patients with metastatic uveal melanoma. Melanoma Res. 2005;15:447451.
  • 37
    Danielli R, Ridolfi R, Chiarion-Sileni V, et al. Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. Cancer Immunol Immunother. 2012;61:4148.
  • 38
    Hofmann UB, Kauczok-Vetter CS, Houben R, Becker JC. Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate. Clin Cancer Res. 2009;15:324329.
  • 39
    Mahipal A, Tijani L, Chan K, Laudadio M, Mastrangelo MJ, Sato T. A pilot study of sunitinib malate in patients with metastatic uveal melanoma. Melanoma Res. 2012;22:440446.
  • 40
    Penel N, Delcambre C, Durando X, et al. O-Mel-Inib: a Cancéro-pôle Nord-Ouest multicenter phase II trial of high-dose imatinib mesylate in metastatic uveal melanoma. Invest New Drugs. 2008;26:561565.
  • 41
    Piperno-Neumann S, Servois V, Bidard F-C, et al. BEVATEM: Phase II study of bevacizumab in combination with temozolomide in patients with first-line metastatic uveal melanoma: Final results. J Clin Oncol. 2013;31:(suppl). Abstract 9057.
  • 42
    Rimoldi D, Salvi S, Liénard D, et al. Lack of BRAF mutations in uveal melanoma. Cancer Res. 2003;63:57125715.
  • 43
    Zuidervaart W, van Nieuwpoort F, Stark M, et al. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Br J Cancer. 2005;92:20322038.
  • 44
    Leyvraz S, Suciu S, Piperno-Neumann S, et al. Randomized phase III trial of intravenous versus hepatic intra-arterial fotemustine in patients with liver metastases from uveal melanoma: Final results of the EORTC 18021 study. J Clin Oncol. 2012;30:(suppl). Abstract 8532.
  • 45
    Pingpank JF, Hughes MS, Alexander HR, et al. Percutaneous hepatic perfusion with melphalan vs. best alternative care for patients with melanoma liver metastases: efficacy update of the phase III trial (NCT00324727). J Clin Oncol. 2010;28(suppl). Abstract LBA8512.
  • 46
    Becker JC, Terheyden P, Kämpgen E, et al. Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2. Br J Cancer. 2002;87:840845.
  • 47
    Agarwala SS, Panikkar R, Kirkwood JM. Phase I/II randomized trial of intrahepatic arterial infusion chemotherapy with cisplatin and chemoembolization with cisplatin and polyvinyl sponge in patients with ocular melanoma metastatic to the liver. Melanoma Res. 2004;14:217222.
  • 48
    Farolfi A, Ridolfi L, Guidoboni M, et al. Liver metastases from melanoma: hepatic intra-arterial chemotherapy. A retrospective study. J Chemother. 2011;23:300305.
  • 49
    Heusner TA, Antoch G, Wittkowski-Sterczewski A, et al. Transarterial hepatic chemoperfusion of uveal melanoma metastases: survival and response to treatment. Rofo. 2011;183:11511160.
  • 50
    Peters S, Voelter V, Zografos L, et al. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. Ann Oncol. 2006;17:578583.
  • 51
    Siegel R, Hauschild A, Kettelhack C, Kähler KC, Bembenek A, Schlag PM. Hepatic arterial Fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma. Eur J Surg Oncol. 2007;33:627632.
  • 52
    Ahrar J, Gupta S, Ensor J, et al. Response, survival, and prognostic factors after hepatic arterial chemoembolization in patients with liver metastases from cutaneous melanoma. Cancer Invest. 2011;29:4955.
  • 53
    Edelhauser G, Schicher N, Berzaczy D, et al. Fotemustine chemoembolization of hepatic metastases from uveal melanoma: a retrospective single-center analysis. AJR Am J Roentgenol. 2012;199:13871392.
  • 54
    Gupta S, Bedikian AY, Ahrar J, et al. Hepatic artery chemoembolization in patients with ocular melanoma metastatic to the liver: response, survival, and prognostic factors. Am J Clin Oncol. 2010;33:474480.
  • 55
    Patel K, Sullivan K, Berd D, et al. Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study. Melanoma Res. 2005;15:297304.
  • 56
    Schuster R, Lindner M, Wacker F, et al. Transarterial chemoembolization of liver metastases from uveal melanoma after failure of systemic therapy: toxicity and outcome. Melanoma Res. 2010;20:191196.
  • 57
    Sharma KV, Gould JE, Harbour JW, et al. Hepatic arterial chemoembolization for management of metastatic melanoma. AJR Am J Roentgenol. 2008;190:99104.
  • 58
    Sato T, Eschelman DJ, Gonsalves CF, et al. Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocyte-macrophage colony-stimulating factor. J Clin Oncol. 2008;26:54365442.
  • 59
    Eschelman DJ, Gonsalves CF, Terai M, et al. The results of a randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor (GM-CSF) in uveal melanoma patients with hepatic metastasis. J Clin Oncol. 2011;29(suppl). Abstract 8577.
  • 60
    Gonsalves CF, Eschelman DJ, Sullivan KL, Anne PR, Doyle L, Sato T. Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single-institution experience. AJR Am J Roentgenol. 2011;196:468473.
  • 61
    Alexander HR, Butler CC. Development of isolated hepatic perfusion via the operative and percutaneous techniques for patients with isolated and unresectable liver metastases. Cancer J. 2010;16:132141.
  • 62
    Vahrmeijer AL, van de Velde CJ, Hartgrink HH, Tollenaar RA. Treatment of melanoma metastases confined to the liver and future perspectives. Dig Surg. 2008;25:467472.
  • 63
    Pingpank JF, Hughes M, Alexander HR, et al. Percutaneous hepatic perfusion (PHP) vs. best alternative care for patients with melanoma liver metastases: efficacy update of the phase 3 trial (NCT00324727). Eur J Cancer. 2011;47(suppl 1):S653. Abstract 9304.
  • 64
    Alexander HR, Libutti SK, Bartlett DL, Puhlmann M, Fraker DL, Bachenheimer LC. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res. 2000;6:30623070.
  • 65
    Alexander HR, Libutti SK, Pingpank JF, et al. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res. 2003;9:63436349.
  • 66
    van Iersel LB, Hoekman EJ, Gelderblom H, et al. Isolated hepatic perfusion with 200 mg melphalan for advanced noncolorectal liver metastases. Ann Surg Oncol. 2008;15:18911988.
  • 67
    Onken MD, Worley LA, Char DH, et al. Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology. 2012;119:15961603.